Ascletis Announces Phase III Trial of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne, Meets All Endpoints ...Middle East

Denifanstat (ASC40), a once-daily oral fatty acid synthase (FASN) inhibitor, demonstrated statistically significant and clinically meaningful improvement compared to placebo in all primary, key secondary, and secondary endpoints Denifanstat demonstrated a favorable safety and tolerability...

Read More Details
Finally We wish PressBee provided you with enough information of ( Ascletis Announces Phase III Trial of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne, Meets All Endpoints )

Also on site :

• George Strait, 73, Goes Viral for Wildly Generous Gift to Wounded Military Veteran
• Two Minors Admit to Felony Charges following Bomb and Shooting Threat at Ventura High School
• 2000s Rock Icon Makes Jaw-Dropping Career Move & Fans Are Here for It